The IL27 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the human IL27 gene in the MCF-7 breast adenocarcinoma epithelial cell line. This loss-of-function model provides researchers with a powerful tool to investigate the complex roles of the IL-27 cytokine in cancer biology, immune regulation, and signal transduction. Unlike monoclonal knockout cell lines, this polyclonal population retains genetic heterogeneity, enabling robust functional studies while minimizing clonal artifacts. The knockout cells are suitable for a wide range of assays, including gene expression analysis, protein signaling, and phenotypic screening, facilitating dissection of IL27-mediated pathways in a hormone-responsive breast cancer context.
The MCF-7 cell line is a well-characterized model of estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) breast adenocarcinoma of the luminal A subtype. Derived from the pleural effusion of a metastatic mammary carcinoma, MCF-7 cells exhibit hormone-dependent growth and serve as a standard platform for studying cell proliferation, apoptosis, and endocrine therapy resistance. Their epithelial morphology and stable karyotype make them amenable to CRISPR/Cas9 editing and downstream functional assays. By knocking out IL27 in this background, researchers can directly assess the contribution of autocrine or paracrine IL-27 signaling to the malignant phenotype and tumor microenvironment interactions.
IL27 encodes the p28 subunit of the heterodimeric cytokine IL-27, which pairs with the EBI3 subunit. Secreted IL-27 binds to the IL27RA/gp130 receptor complex, activating associated Janus kinases JAK1, JAK2, and TYK2, which phosphorylate and activate STAT1 and STAT3 transcription factors. This signaling cascade induces expression of key downstream targets such as T-bet, IL-10, SOCS3, and PD-L1, while also promoting CXCL10 and granzyme B production. The pathway is further modulated by upstream regulators including TLR4 ligands, IFN-??, CD40L, NF-??B, IRF1, and IRF3. Through STAT1/STAT3, IL-27 drives Th1 differentiation and suppresses Th17 responses, exhibiting dual pro-inflammatory and anti-inflammatory functions essential for balancing T cell immunity. In the tumor microenvironment, IL-27 can shape immune surveillance and inflammation.
In ER-positive breast cancer, emerging evidence suggests that IL-27 may influence tumor progression by modulating JAK-STAT target genes, cytokine profiles, and immune checkpoint molecules. The IL27 Knockout MCF-7 Polyclonal Cells allow direct interrogation of these mechanisms, particularly how loss of p28 subunit expression affects STAT1/STAT3 phosphorylation dynamics and downstream transcriptional programs. Researchers can explore whether IL-27 deficiency alters the expression of immune-regulatory factors like PD-L1 or CXCL10, thereby affecting T cell responses and tumor immune escape. This knockout model is instrumental for dissecting the intersection of hormone signaling and cytokine networks, and for identifying potential vulnerabilities in ER+ breast cancers that rely on IL-27-mediated pathways for growth or immune evasion.
These polyclonal knockout cells are ideal for a variety of advanced research applications, including functional studies of IL27 in breast cancer immunology, screening for modulators of IL-27-mediated immune checkpoints, and investigation of tumor cell?CT cell crosstalk. Representative assays include RT-qPCR and western blotting to confirm knockout and assess downstream targets (e.g., phospho-STAT1/STAT3), ELISA for IL-10 and IFN-?? secretion, cell proliferation (MTS) and apoptosis (Annexin V) assays, and transwell migration/invasion studies. The cells are also compatible with RNA-seq transcriptomics and co-culture systems with primary T cells to evaluate immunomodulatory effects. For further details, please contact Ascent Research.
